Edwards Lifesciences holders should expect gains from acquisition, Barron's says Edwards Lifesciences acquired CardiAQ and received two upgrades; shareholders should expect more gains, despite the stock's expensive price, Barron's contends in its 'Barron's Take' column. Reference Link
Edwards Lifesciences upgraded to Outperform from Market Perform at Northland Northland upgraded Edwards Lifesciences to Outperform citing the acquisition of CardiAQ, an early-stage company developing a TMVI system. The firm views the acquisition as a smart as it jump starts the TMVI program and adds a wealth knowledge from the principals who have a prior background at CoreValue. Northland increased Edwards Lifesciences' price target to $170 from $140 on shares.
Canaccord recommends Edwards Lifesciences, Neovasc in TMVR sector Canaccord said they continue to like both Edwards Lifesciences (EW) and Neovasc (NVCN) in the transcatheter mitral valve replacement, or TMVR, space. The firm sees long term growth potential in the TMVR space and upside earnings and revenue potential in Edwards due to its leverage there and its acquisition of privately held CardiAQ. The firm said the removal of CardiAQ as a competitor should be positive for Neovasc and has a Buy rating on both stocks.